Cotización Daxor - DXR

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

10.877

Postura de Compra

Postura de Venta

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

57.833M

Precio Anterior

10.877

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

5,317,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

177.08

Beneficio por acción (BPA)

0.05

turnover

163k

Beneficio neto

281k

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and compos... Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions. Mostrar más

Sector

Surgical,med Instr,apparatus

Industria

Misc Health & Allied Svc,nec

Sitio web

www.daxor.com

Sede

Oak Ridge, New Jersey, USA

Fundado

2010

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers...

Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022

Oak Ridge, TN, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The...

Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...

DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...

DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

Method Patent Covers Blood Volume Analysis Technology to Evaluate and Guide Treatment Decisions in Multiple Medical Conditions Oak Ridge, TN, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021...

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...

Daxor Corporation Receives $200K Matching Fund Award from Launch Tennessee

The SBIR/STTR Matching Fund Grant Will Advance the Company’s Innovation and Commercialization Efforts, and Job Creation Oak Ridge, TN, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:...

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Data from Three New Studies and Two Ongoing Trials Presented at the Heart Failure Society of America Annual Scientific Meeting 2021 Data Highlight Importance of Blood Volume Analysis in Providing...

Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021

Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, , today announced it will exhibit at the Heart Failure...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BATLBattalion Oil Corporation	US$ 6.5321 (122.18%)	1.46M
NBYNovaBay Pharmaceuticals Inc New	US$ 0.7087 (42.62%)	145.45M
INLXIntellinetics Inc	US$ 11.30 (19.58%)	29.43k
MGLDMarygold Companies Inc	US$ 1.52 (16.92%)	12.68k
XTNTXtant Medical Holdings Inc	US$ 0.664 (16.90%)	420.12k
SGNSigning Day Sports Inc	US$ 0.2699 (-49.08%)	24.3M
AIMAIM ImmunoTech Inc	US$ 0.2199 (-24.43%)	1.53M
HCWCHealthy Choice Wellness Corp	US$ 2.34 (-21.21%)	334.26k
NRXSNeuraxis Inc	US$ 2.56 (-12.63%)	28.63k
RVPRetractable Technologies Inc	US$ 0.7875 (-12.39%)	857.17k
NBYNovaBay Pharmaceuticals Inc New	US$ 0.7087 (42.62%)	145.47M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 33.55 (-4.47%)	108.52M
BTGB2Gold Corp	US$ 3.36 (1.51%)	81.45M
SPYSPDR S&P 500	US$ 568.25 (-0.48%)	80.45M
SOXSDirexion Daily Semiconductor Bear 3X Shares New	US$ 22.70 (4.42%)	62.79M